June 2019

Column

Editor's Page

Predictive Methodologies to Better Manage Costs of Innovative Therapies

06/18/2019

Winston Wong, PharmD, Editor-in-Chief

Novel innovations in cell and gene therapies mark a new era in medicine whereby durable remission, and potentially cures, are within reach for several diseases. These advancements are clearly beneficial and have been...

Novel...

06/18/2019

Journal of Clinical Pathways

Editorial

The Real-Life Patient Impact of Pharmacy Benefit Managers

06/18/2019

Nicolas Ferreyros, Managing Director, Community Oncology Alliance

The Centers for Medicare & Medicaid Services (CMS) recently released a final rule for Medicare Part D that codified its decision to allow Medicare Advantage plans to use step therapy, or “fail first,” for new...

The...

06/18/2019

Journal of Clinical Pathways

Pharma Insights

Evolution of Hub Services

06/18/2019

Chris Dillon BS

Chrysanthe Peteros, MPH

Larry Blandford, PharmD—Column Editor

What began as patient call centers for select complex medicines has expanded to a full suite of support services, ranging from financial assistance to patient education: so-called hub services have become ubiquitous...

What...

06/18/2019

Journal of Clinical Pathways

Business of Pathways

Cell and Gene Therapies: Paying It Forward and Adjusting Payment Systems for the Age of Cures

06/18/2019

Sean McElligott, MS

Ira Klein, MD, MBA, FACP—Column Editor

Cell and gene therapies represent the next frontier of pharmaceutical development, holding the promise of delivering potentially curative therapies for diseases that have limited treatment options. However, these...

Cell...

06/18/2019

Journal of Clinical Pathways

News

Conference Coverage

American Society of Clinical Oncology 2019 Annual Meeting

06/18/2019

JCP Editors

The American Society of Clinical Oncology (ASCO) is the leading professional organization for physicians and oncology professionals caring for people with cancer. Through its multidisciplinary network of almost...

The...

06/18/2019

Journal of Clinical Pathways

Department

Clinical Pathways Forum

Oncology Clinical Pathways: The Yale Experience

06/18/2019

Mishellene McKinney, MHA, RN, OCN

Founded in 2016, the Clinical Pathways Forum is a community of pathways professionals—now totaling over 12 institutions from across the United States and Canada—who are utilizing clinical pathways in their practices...

...

06/18/2019

Journal of Clinical Pathways

Feature

Research Reports

Drug Costs vs Probability of Survival in Lung Cancer: Impact of Dosage, Duration, and Immune Checkpoint Inhibitor Combinations

06/18/2019

Helmy M Guirgis, MD

Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-small cell lung cancer (amNSCLC). There is an unmet need...

...

06/18/2019

Journal of Clinical Pathways

Perspectives

On the Horizon for Value-Based Oncology Care: Predictive Analytics, Novel Therapy Pricing Pressures, New Payment Models, and a Rise in Complex Data Sources

06/18/2019

Charles Saunders, MD

Jennifer Webster, MS

Abstract: January 2019 represented another major inflection point for the Oncology Care Model (OCM), marking the halfway point of the 5-year program. Overall, while OCM participants have expressed concerns about...

...

06/18/2019

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

June 2019

Column

News

Department

Feature

Current Issue

Special Reports

Subscribe

Volume 5

Specialties

Events

Year Round Education

HMP Global Products